Phaseline

Targets › ALK2

ALK2: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Other; next expected readout Jul 2027.

Open in Phaseline: the race on ALK2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
IncyteINCB000928
ALK2 (activin receptor-like kinase 2) inhibitor
ALK2Phase 2Fibrodysplasia Ossificans Progressiva (FOP)Jul 2027

Conditions

Fibrodysplasia Ossificans Progressiva (FOP) (1)

Modalities

small molecule (1)

Companies

Incyte (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.